PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals
Executive Summary
Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
CDER, CBER Post FY 2023 Employee Gains, But Behind User Fee Hiring Goals
US FDA’s drug center reported a net increase of more than 300 employees in FY 2023, while the biologics center saw an overall increase of more than 30.
US FDA’s Gene Therapy Office Poaches OCE’s Fashoyin-Aje For Oncology Position
Lola Fashoyin-Aje, formerly associate director of the Oncology Center of Excellence, will become director of the CBER Office of Therapeutic Products’ Office of Clinical Evaluation.